Study of N-acetyl-L-leucine for CACNA1A disorders
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests a potential treatment for people with CACNA1A disorders, which can cause movement problems, migraine, or seizures. The medication may help improve balance and coordination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be at least 4 years old.
- You must have a confirmed genetic diagnosis of a CACNA1A disorder.
- You need to have some trouble with balance or coordination, but be able to walk a short distance or do a pegboard test within a certain time.
- You must weigh at least 33 pounds (15 kg).
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study.
- You must agree to not use certain medications or take part in other clinical trials during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with certain types of spinocerebellar ataxia (a group of conditions that cause progressive movement problems) to understand how the disease changes over time and how genes might influence it. It may help researchers learn more about these conditions and support future treatments.
This study tests whether N-acetyl cysteine (a supplement-like medicine) changes body and brain function in people with multiple sclerosis. It may help researchers understand how it affects brain chemistry and activity using special brain imaging.
This Phase 2 trial tests whether a supplement-like medicine called N-acetylcysteine (NAC) can reduce repetitive behaviors and self-injurious behaviors in people with Cornelia de Lange syndrome (CdLS). It also checks safety over about 18 weeks at Johns Hopkins Hospital.
This Phase 3 trial tests whether N-acetyl-leucine can improve symptoms in people with Niemann-Pick disease type C (NPC). If you qualify, you will be asked to take study medicine and complete symptom and movement tests over time.
This trial tests if acetyl-leucine can help improve walking and balance in people who had a specific type of stroke in the back part of the brain. You may qualify if you had your first stroke there and have trouble with balance or walking.
This Phase 2 study tests whether NAC (a supplement-like medicine) can delay symptoms in people who carry the Huntington’s disease gene expansion but do not yet have clear movement symptoms. You may be asked to take NAC and attend regular visits, scans, and blood tests to see if it changes how likely you are to develop Huntington’s disease within the next 10 years.
Hear when a new Spinocerebellar Ataxia Type 6 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.